Naltrexone and Poor venous access - a phase IV clinical study of FDA data

Summary:

Poor venous access is reported as a side effect among people who take Naltrexone (naltrexone), especially for people who are female, 30-39 old, also take Prednisone, and have Crohn's disease.

The phase IV clinical study analyzes which people have Poor venous access when taking Naltrexone. It is created by eHealthMe based on reports of 4,805 people who have side effects when taking Naltrexone from the FDA, and is updated regularly.

What is Naltrexone?

Naltrexone has active ingredients of naltrexone. eHealthMe is studying from 4,835 Naltrexone users. Check the latest studies of Naltrexone.

What is Poor venous access?

Poor venous access is found to be associated with 677 drugs and 480 conditions by eHealthMe. Check the latest studies of Poor venous access.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 31, 2026

4,805 people reported to have side effects when taking Naltrexone.
Among them, 16 people (0.33%) have Poor venous access.

Could Naltrexone cause Poor venous access?

Among these 16 people:

What is the gender of people who have Poor venous access when taking Naltrexone? *

female: 90 %
male: 10 %

What is the age of people who have Poor venous access when taking Naltrexone? *

What are other drugs people take besides Naltrexone? *

What are other side effects people have besides Poor venous access? *

Infusion Site Swelling: 10 people, 62.50%
Infusion Site Extravasation (flow of (blood or lymph) from infusion site): 10 people, 62.50%
Feeling Abnormal: 10 people, 62.50%
Tenderness (pain or discomfort when an affected area is touched): 10 people, 62.50%
Cellulitis (infection under the skin): 10 people, 62.50%
Infusion Site Erythema (reddening of the skin at infusion site): 10 people, 62.50%
Drug Level Below Therapeutic: 7 people, 43.75%
Migraine (headache): 7 people, 43.75%
Abscess (pus): 7 people, 43.75%
Therapeutic Response Decreased (less preventive response): 7 people, 43.75%

What are the existing conditions these people have? *

Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 12 people, 75.00%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 4 people, 25.00%
Weight Loss: 1 person, 6.25%
Pain: 1 person, 6.25%
Insomnia (sleeplessness): 1 person, 6.25%
Fibromyalgia (a long-term condition which causes pain all over the body): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Naltrexone and have Poor venous access?

- Check whether Poor venous access is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Naltrexone:

Naltrexone (4,835 reports)

Browse all side effects of Naltrexone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Poor venous access:

Poor venous access (677 drugs)

Browse all the conditions that are associated with Poor venous access:

Poor venous access (480 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on naltrexone (the active ingredients of Naltrexone) and Naltrexone (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.